An Innovative In Vivo Model for CAR-T-Cell Therapy Development: Efficacy Evaluation of CD19-Targeting CAR-T Cells on Human Lymphoma, Using the Chicken CAM Assay
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27020795 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Yan Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Inovotion, 38700 La Tronche, France. Hauptthemen laut MEDLINE: Lymphoma, Chorioallantoic Membrane, Immunotherapy, Adoptive, Antigens, CD19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GRENOBLE-ALPES METROPOLE and BPI France, Grenoble-Alpes Métropole and BPI France.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)-T-cell therapy is a revolutionary approach in immunotherapy that has shown remarkable success in the treatment of blood cancers. Many preclinical studies are currently underway worldwide to extend the CAR-T-cell therapy benefits to a broad spectrum of cancers, using rodent models. Alternative in vivo platforms are essential for overcoming the drawbacks associated with rodent models, including immunodeficiency in humanized models, ethical concerns, extended time requirements, and cost. In this work, we used the chicken chorioallantoic membrane (CAM) assay to evaluate the in vivo efficacy of cluster-of-differentiation 19 (CD19)-targeting CAR-T cells expressing a second-generation CAR construct against human lymphoma derived from the Raji cell line. Our results confirm the efficacy of selected CAR-T cells on tumor growth, metastasis, and angiogenesis. Further, the chicken embryo has an intrinsic active immune system. Therefore, the dialog between CAR-T cells and endogenous immune cells, as well as their participation in the tumor challenge, has also been studied. In conclusion, our study demonstrates that the chicken CAM assay provides a relevant in vivo, 3Rs (Replacement, Reduction and Refinement)-compliant new approach methodology (NAM), which is well-suited for the current needs of preclinical research on CAR-T-cell therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inovotion, 38700 La Tronche, France.
- Allogenica, 69008 Lyon, France.
- Institute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, 38000 Grenoble, France.
ORCID-Profile: Yan Wang, Chloé Prunier, Xavier Rousset, Anthony Lucas
Förderung
- GRENOBLE-ALPES METROPOLE and BPI France
- Grenoble-Alpes Métropole and BPI France
Zitieren
APA
Wang, Y., Prunier, C., Menkova, I., Rousset, X., Lucas, A., Abel, T., & Viallet, J. (2026). An Innovative In Vivo Model for CAR-T-Cell Therapy Development: Efficacy Evaluation of CD19-Targeting CAR-T Cells on Human Lymphoma, Using the Chicken CAM Assay. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020795
Vancouver
Wang Y, Prunier C, Menkova I, Rousset X, Lucas A, Abel T, et al. An Innovative In Vivo Model for CAR-T-Cell Therapy Development: Efficacy Evaluation of CD19-Targeting CAR-T Cells on Human Lymphoma, Using the Chicken CAM Assay. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27020795
BibTeX
@article{Wang2026,
author = {Wang, Yan and Prunier, Chloé and Menkova, Inna and Rousset, Xavier and Lucas, Anthony and Abel, Tobias and Viallet, Jean},
title = {An Innovative In Vivo Model for CAR-T-Cell Therapy Development: Efficacy Evaluation of CD19-Targeting CAR-T Cells on Human Lymphoma, Using the Chicken CAM Assay},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27020795}
}
EUVIMED